Sort
23,748 grants matching “melanoma”
(8) Mechanisms of autoimmune endocrine diseases in patients receiving checkpoint inhibitors
$554,845Kevan C Herold · Yale University · R01 · FY2022 · CA
OCULAR MELANOMA
$554,797University Of Pennsylvania · U10 · FY2001 · EY
Optimized ex vivo expansion of anti-tumor Th1 and Tc1 for adoptive immunotherapy
$554,758Mary L. Disis · University Of Washington · R01 · FY2013 · CA
Processed Antigen Characterization by Mass Spectrometry
$554,586Donald F Hunt · University Of Virginia · R01 · FY2011 · AI
EVALUATING HETEROGENEITY AND RESPONSE TO TREATMENT IN MELANOMA USING CIRCULATING TUMOR CELLS
$554,400University Of California, Los Angeles · · FY2017 · Department of the Army
Characterizing and predicting colitis in immune checkpoint blockade-treated cancer patients
$554,399Sacha Gnjatic · Icahn School Of Medicine At Mount Sinai · U01 · FY2024 · DK
Integrative Cancer Genomics: Drivers, Pathways and Drugs
$554,295Dana Pe'er · Columbia Univ New York Morningside · R01 · FY2015 · CA
Regulation of the Melanocyte Lineage by the AP2 Transcription Factor Family
$554,235Robert Aaron Cornell · University Of Iowa · R01 · FY2020 · AR
Progressive acquisition of novel neural crest derivatives along the neural axis during vertebrate evolution
$554,186Marianne Bronner-Fraser · California Institute Of Technology · R35 · FY2024 · NS
The Antiproliferative Activities of Human Interferons
$554,055Kathryn Zoon · National Institute Of Allergy And Infectious Diseases · ZIA · FY2009 · AI
Stromal Regulation of Basal Cell Carcinoma Formation
$554,038Anthony E Oro · Stanford University · R01 · FY2022 · AR
Modifying Young Adult Skin Cancer Risk and Protective Behaviors (UV4.me2):A Hybrid Type 2 Dissemination/Effectiveness Trial
$553,945Carolyn J. Heckman · Rbhs -Cancer Institute Of New Jersey · R01 · FY2018 · CA
Low Dose Interleukin-2 for Regulatory T cell Modulation and the Treatment of CrohnâÂÂs Disease
$553,742Scott B Snapper · Boston Children'S Hospital · R01 · FY2021 · DK
Role of IRF2 in cancer immune evasion and immunotherapy
$553,729Kenneth L Rock · Univ Of Massachusetts Med Sch Worcester · R01 · FY2024 · CA
THERAPEUTIC MANUFACTURING
$553,636Leland H Hartwell · Fred Hutchinson Cancer Research Center · P30 · FY2009 · CA
TCR signaling and cell cycle regulation in tumor-specific CD8 T cell dysfunction
$553,614Mary Philip · Vanderbilt University Medical Center · R37 · FY2025 · CA
The KIT Signaling Pathway as a Therapeutic Target in Melanoma
$553,458Boris C Bastian · Wistar Institute · P01 · FY2011 · CA
Indoor Tanning Use, DNA Repair and Risk of Melanoma
$553,275University Of Minnesota Twin Cities · R01 · FY2005 · CA
RARE EARTH NANOPROBES FOR OPTICAL IMAGING AND DISEASE TRACKING
$553,271Prabhas V Moghe · Rutgers, The State Univ Of N.J. · R01 · FY2014 · EB
Optimizing Novel Immunotherapy Combinations Targeting the Tumor Microenvironment in Canine Spontaneous Osteosarcoma
$553,260Steven W. Dow · Colorado State University · U01 · FY2020 · CA
Combating melanoma resistance by targeting ABL1/2
$553,135Rina Plattner · University Of Kentucky · R01 · FY2024 · CA
Targeting PIM-2 Kinase for Improving Cancer Immunotherapy
$552,877Xue-Zhong Yu · Medical College Of Wisconsin · R01 · FY2022 · CA
Discovery of Somatic Noncoding Variants that Serve as Drivers in Pediatric Cancers
$552,832Jinghui Zhang · St. Jude Children'S Research Hospital · R01 · FY2022 · CA
MELANOMA-ASSOCIATED LYMPHANGIOGENESIS, IMMUNE SUPPRESSION, AND RESPONSE TO TARGETED THERAPY
$552,629Oregon Health & Science University · · FY2015 · Department of Defense
Understanding Immunotype, a Novel Biomarker for Checkpoint Blockade Resistance
$552,595Margaret Kathleen Callahan · University Of Connecticut Sch Of Med/Dnt · R01 · FY2025 · CA